AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02901028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory testing
Description: Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
Study NCT03309475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SocialMIND
Description: SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
Study NCT03309475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational multicomponent intervention
Description: The psychoeducational multicomponent intervention addresses and discuss several aspects of great importance for persons who suffer a first episode of psychosis, such as biased perception and thinking, delusions-related anxiety or the nature of hallucinations. Its aim is to encourage patients to reflect upon their experiences from a critic perspective.
Study NCT03309475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Treatment as usual delivered by patient's practitioner
Study NCT03309475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment
Description: Treatment as usual delivered by patient's practitioner
Study NCT02901028 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood and Urine Draws
Description: subjects will have a blood draw and provide a urine sample
Study NCT02901028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and Urine Draws
Description: subjects will have a blood draw and provide a urine sample
Study NCT02993562 — intervention group
Intervention type: DRUG
Intervention: Levothyroxine
Description: Normal treatment with levothyroxine.
Study NCT00833534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00833534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study NCT01246687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Intervention
Description: Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
Study NCT03216967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Patients with viremia above 2.8 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
Study NCT04578080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
Study NCT03216967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: Patients with viremia above 2.8 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
Study NCT04210557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. An electric pulse generator, or stimulator, is connected to a magnetic coil, which in turn is connected to the scalp. The stimulator generates a changing electric current within the coil which induces a magnetic field; this field then causes a second inductance of inverted electric charge within the brain itself.
Study NCT03030664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L.reuteri
Description: Each day, at about the same time, the subjects will be given 5 drops (1x10\^8 CFU) of the study product in connection with feeding
Study NCT03030664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same formulation as study product, without probiotics.
Study NCT02475213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
Study NCT03309475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psychotropic treatment
Description: Treatment as usual delivered by patient's practitioner
Study NCT03309475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychotropic treatment
Description: Treatment as usual delivered by patient's practitioner
Study NCT02681432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
Study NCT02681432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No HIPEC
Description: Cytoreductive surgery without HIPEC
Study NCT00850187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow derived mesenchymal stem cells
Description: Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
Study NCT04578080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Anodal or Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
Study NCT03920020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the concentric isokinetic exercise group
Description: concentric isokinetic exercises
Study NCT03920020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the eccentric isokinetic exercise group
Description: eccentric isokinetic exercises
Study NCT03920020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the control group
Description: conventional physiotherapy and standard therapeutic exercises predetermined by us
Study NCT01367756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4995819
Description: multiple oral doses, Days 10-16
Study NCT01367756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: multiple oral doses, Days 1-16
Study NCT01367756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: citalopram
Description: multiple oral doses, Days 1-16
Study NCT01367756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple oral doses, Days 10-16
Study NCT05960123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubularized Incised Plate (TIP) urethroplasty
Description: tubularization of urethral plate with or without spongioplasty
Study NCT00414609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren was available in 75 mg tablet, 150 mg tablet
Study NCT00414609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
Study NCT01819480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery
Description: Transoral robotic surgery using the daVinci robot to remove primary tumor
Study NCT01169909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
Study NCT02884960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine Fibroid Embolization
Description: This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
Study NCT02884960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Fibroid Embolization
Description: This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
Study NCT02256800 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping (6,6)
Description: The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2.
Study NCT02256800 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGTIA1 genotyping (6,7)
Description: The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2.
Study NCT02195687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
Study NCT02195687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
Study NCT00479583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-690514 / FOLFIRI
Description: Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
Study NCT00479583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-690514 / FOLFOX
Description: Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
Study NCT02905435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable Temporizing Matrix
Description: The Biodegradable Temporizing Matrix (BTM) (also known as NovoSorb BTM) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
Study NCT02475213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGA012
Description: anti-PD-1 monoclonal antibody
Study NCT02502305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: liveonline course
Description: physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
Study NCT03685708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV-B
Description: HEPLISAV-B (Hepatitis B Vaccine \[Recombinant \], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
Study NCT01704105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water Quality
Description: Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
Study NCT01704105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sanitation
Description: Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
Study NCT02256800 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGTIA1 genotyping (7,7)
Description: The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2.
Study NCT02256800 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UGT1A1 non-genotyping
Description: The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
Study NCT02256800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Description: bevacizumab as target therapy
Study NCT02256800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan as escalating dose according to UGT1A1 genotyping
Study NCT02256800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: combined with 5-FU
Study NCT02256800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: combined with irinotecan
Study NCT00805376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNX-2401
Description: Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
Study NCT00805376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Removal
Description: Surgical Tumor Resection
Study NCT04041791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzyl penicillin
Description: Benzyl penicillin is a penicillin antibiotic.
Study NCT04041791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzyl penicillin
Description: Benzyl penicillin is a penicillin antibiotic.
Study NCT04041791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin Sulfate
Description: Gentamicin is an aminoglycoside antibiotic.
Study NCT04041791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate
Description: Gentamicin is an aminoglycoside antibiotic.
Study NCT01704105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Handwashing
Description: Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces.
Study NCT02872688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GanedenBC30
Study NCT04289272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dove Confident Me
Description: Dove Confident Me is a school-based intervention co-created by researchers at La Trobe University (Australia), the Centre for Appearance Research UWE, teachers, students, and education experts, and the Dove Self-Esteem Project (the social mission for personal care brand Dove). The five-session intervention is aimed at adolescents aged between 11-13 years, and targets recognised risk factors for body dissatisfaction, by addressing societal appearance ideals (Session 1), media literacy (Session 2), appearance comparisons (Session 3), appearance-related conversations and teasing (Session 4), and promoting 'body activism' (Session 5). The intervention consists of classroom-based discussion and small group activities, and uses audio-visual materials and worksheets to facilitate learning.
Study NCT01681303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Study NCT01424163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose reduced
Description: Treatment 1 (Part A)
Study NCT02303938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
Study NCT03696667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCI
Description: As participants listen to the music, the EEG waves of their affective states and their variations detected in real-time is converted into an auditory signal providing direct feedback to participants about their affective states and assisting participants to learn and practice emotion regulation.
Study NCT01141543 — intervention group
Intervention type: DRUG
Intervention: Plerixafor (mozobil)
Description: Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN
Study NCT03823885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-cigarette
Description: use e-cig for 30 minutes
Study NCT03823885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: empty (-cigarette sham control)
Description: use empty e-cig (sham control)
Study NCT03002909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Study NCT01424163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose standard
Description: Treatment 2 (Part A)
Study NCT03002909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: preperitoneal catheter
Study NCT01205737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TL011
Description: 375 mg/m2 iv every 3 weeks for 8 cycles
Study NCT01205737 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 iv every 3 weeks for 8 cycles
Study NCT03152890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
Study NCT02681042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure
Description: The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
Study NCT02681042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SentreHeart Lariat®
Description: The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
Study NCT04032431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telerehab VR intervention
Description: Training with VR system using software specifically designed to reproduce activities of daily living
Study NCT04032431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehab VR intervention
Description: Training with VR system using software specifically designed to reproduce activities of daily living
Study NCT04591132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinematic analysis
Description: motor tasks appropriate for each diagnosis will be recorder with wearable inertial sensors
Study NCT01642849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein diet
Description: 6 months on HP diet